Daniel S.W. Tan
YOU?
Author Swipe
View article: Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer
Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer Open
Tumor-initiating cells (TICs) preferentially reside in poorly vascularized, nutrient-stressed tumor regions, yet how they adapt to glucose limitation is unclear. We show that lung TICs, unlike bulk tumor cells, can switch from glucose to k…
View article: Supplementary Figure S4 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S4 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S4. Patient enrollment and disposition in the alternative-schedule dose-escalation cohorts
View article: Supplementary Table S1 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Table S1 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Table S1. Representativeness of study participants
View article: Supplementary Figure S8 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S8 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S8. Evaluation of benefit from elimusertib in patients with specific tumor-associated DDR alterations (A–D)
View article: Supplementary Table S2 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Table S2 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Table S2. Most common all-cause TEAEs occurring in ≥10% of the total population in the dose-expansion and alternative-schedule dose-escalation cohorts
View article: Supplementary Figure S5 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S5 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S5. Pharmacokinetics of elimusertib in the dose-expansion cohorts on cycle 1, day 1 (A) and cycle 1, day 10 (B) and in the alternative-schedule dose-escalation cohorts on cycle 1, day 1 (C) and cycle 1, day 17 (D)
View article: Data from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Data from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
In this phase Ib basket expansion trial and alternative-schedule dose-escalation study, we evaluated the ataxia-telangiectasia and rad3-related (ATR) inhibitor elimusertib at 40 mg twice daily (3 days on/4 days off) in 143 patients with ad…
View article: Supplementary Figure S1 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S1 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S1. Study design for the dose-expansion cohorts
View article: Supplementary Figure S2 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S2 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S2. Patient enrollment and disposition in the dose-expansion cohorts
View article: Supplementary Figure S6 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S6 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S6. Best response, earliest time point, duration of best response, previous PARPi exposure, platinum sensitivity, biomarker status, and duration of treatment in the prostate (A, B), colorectal (C, D), and breast (E, F) cancer dose-e…
View article: Supplementary Figure S7 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S7 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S7. Serial computed tomography imaging at baseline and after elimusertib treatment in a patient with prostate cancer after six cycles of treatment (A) and a patient with ureteral cancer after two cycles of treatment (B)
View article: Supplementary Figure S3 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Figure S3 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Figure S3. Study design for the alternative-schedule dose-escalation cohorts
View article: Supplementary Table S4 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Table S4 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Table S4. Patients in the gynecologic cancer dose-expansion cohort with a treatment response ≥180 days
View article: Supplementary Table S5 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Table S5 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Table S5. Correlation of alterations detected in baseline plasma (ctDNA) and tumor tissue (NGS)
View article: Supplementary Table S3 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Supplementary Table S3 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects Open
Table S3. Single- and multiple-dose pharmacokinetics from the dose-expansion and alternative-schedule dose-escalation cohorts (pharmacokinetic analysis set)
View article: Improving immune‐related health outcomes post‐cesarean birth with a gut microbiome‐based program: A randomized controlled trial
Improving immune‐related health outcomes post‐cesarean birth with a gut microbiome‐based program: A randomized controlled trial Open
Background Infants born via Cesarean section (C‐section) often have a distinct gut microbiome and higher risks of atopic and immune‐related conditions than vaginally delivered infants. We evaluated whether a microbiome‐based program could …
View article: Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab Open
PURPOSE To evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutat…
View article: Figure 4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
PFS by treatment in: (A) CD8 low and PD-L1 <1%; (B) CD8 low and PD-L1 ≥1%; (C) CD8 high and PD-L1 <1%; (D) CD8 high and PD-L1 ≥1%. OS by treatment in: (E) CD8 low and PD-L1 <1%; (F) CD8 low and PD-L1 ≥1%; (G) CD8 high and PD-L1 <1%; (H) CD…
View article: Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CANOPY-1 and B, CANOPY-N study designs.
View article: Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S10 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Changes in T-cell phenotype distribution from screening to surgery for CANOPY-N as A, a T-cell phenotype count and B, a fraction of the total phenotypes per arm/time point.
View article: Figure S9 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S9 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Distribution of T-cell subgroups in CANOPY-1 using A, dimension 1, total immune infiltration and B, dimension 2, balance between immune suppressive signatures and antitumor immunity.
View article: Figure 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
(A) PFS and (B) OS by CD8 IHC (low and high by median cutoff); (C) PFS and (D) OS by CD8 phenotype; and (E) PFS and (F) OS by T-cell–inflamed gene signature (low and high by median cutoff) in CANOPY-1.
View article: Data from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Data from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Preclinical studies have shown that interleukin (IL)-1β blockade can modulate the tumor microenvironment (TME) to activate antitumor immunity and, in combination with immune checkpoint inhibitors (ICIs), prevent cancer growth. Our study in…
View article: Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S4 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Cell phenotypes assessed by QIF: A, CD11b/CD66b stained for polymorphonuclear granulocytes (or neutrophils); B, CD163 stained for monocyte-lineage macrophages (or tumor-associated macrophages); and C, FOXP3/CD3 stained for regulatory T cel…
View article: Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S7 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
A, CD8 central tumor levels by PD-L1 subgroups and B, summary of patient characteristics at baseline by PD-L1 subgroup for CANOPY-1.
View article: Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Figure S5 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Comparison of CD8 subgroups (median cut-off) with T-cell phenotypes for CANOPY-1, by A, CD8 level and B, T-cell phenotype.
View article: Table 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Table 1 from The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials Open
Baseline characteristics for CANOPY-1 and CANOPY-N population subsets